Literature DB >> 32350063

Regional Proteomic Quantification of Clinically Relevant Non-Cytochrome P450 Enzymes along the Human Small Intestine.

Haeyoung Zhang1, Chris Wolford1, Abdul Basit1, Albert P Li1, Peter W Fan1, Bernard P Murray1, Ryan H Takahashi1, S Cyrus Khojasteh1, Bill J Smith1, Kenneth E Thummel1, Bhagwat Prasad2.   

Abstract

Current challenges in accurately predicting intestinal metabolism arise from the complex nature of the intestine, leading to limited applicability of available in vitro tools as well as knowledge deficits in intestinal physiology, including enzyme abundance. In particular, information on regional enzyme abundance along the small intestine is lacking, especially for non-cytochrome P450 enzymes such as carboxylesterases (CESs), UDP-glucuronosyltransferases (UGTs), and sulfotransferases (SULTs). We used cryopreserved human intestinal mucosa samples from nine donors as an in vitro surrogate model for the small intestine and performed liquid chromatography tandem mass spectrometry-based quantitative proteomics for 17 non-cytochrome P450 enzymes using stable isotope-labeled peptides. Relative protein quantification was done by normalization with enterocyte marker proteins, i.e., villin-1, sucrase isomaltase, and fatty acid binding protein 2, and absolute protein quantification is reported as picomoles per milligram of protein. Activity assays in glucuronidations and sequential metabolisms were conducted to validate the proteomics findings. Relative or absolute quantifications are reported for CES1, CES2, five UGTs, and four SULTs along the small intestine: duodenum, jejunum, and ileum for six donors and in 10 segments along the entire small intestine (A-J) for three donors. Relative quantification using marker proteins may be beneficial in further controlling for technical variabilities. Absolute quantification data will allow for scaling factor generation and in vivo extrapolation of intestinal clearance using physiologically based pharmacokinetic modeling. SIGNIFICANCE STATEMENT: Current knowledge gaps exist in intestinal protein abundance of non-cytochrome P450 enzymes. Here, we employ quantitative proteomics to measure non-cytochrome P450 enzymes along the human small intestine in nine donors using cryopreserved human intestinal mucosa samples. Absolute and relative abundances reported here will allow better scaling of intestinal clearance.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2020        PMID: 32350063     DOI: 10.1124/dmd.120.090738

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

Review 1.  Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.

Authors:  Deepak Ahire; Laken Kruger; Sheena Sharma; Vijaya Saradhi Mettu; Abdul Basit; Bhagwat Prasad
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

2.  Interindividual Variability and Differential Tissue Abundance of Mitochondrial Amidoxime Reducing Component Enzymes in Humans.

Authors:  Deepak Ahire; Abdul Basit; Lisa J Christopher; Ramaswamy Iyer; J Steven Leeder; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2021-12-23       Impact factor: 3.922

Review 3.  Gutsy science: In vitro systems of the human intestine to model oral drug disposition.

Authors:  Christopher M Arian; Tomoki Imaoka; Jade Yang; Edward J Kelly; Kenneth E Thummel
Journal:  Pharmacol Ther       Date:  2021-08-31       Impact factor: 12.310

4.  Ultrasensitive Quantification of Drug-metabolizing Enzymes and Transporters in Small Sample Volume by Microflow LC-MS/MS.

Authors:  Deepak Suresh Ahire; Abdul Basit; Matthew Karasu; Bhagwat Prasad
Journal:  J Pharm Sci       Date:  2021-03-28       Impact factor: 3.784

Review 5.  The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates.

Authors:  Erkka Järvinen; Feng Deng; Wilma Kiander; Alli Sinokki; Heidi Kidron; Noora Sjöstedt
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

Review 6.  3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration.

Authors:  Hongbing Wang; Paul C Brown; Edwin C Y Chow; Lorna Ewart; Stephen S Ferguson; Suzanne Fitzpatrick; Benjamin S Freedman; Grace L Guo; William Hedrich; Scott Heyward; James Hickman; Nina Isoherranen; Albert P Li; Qi Liu; Shannon M Mumenthaler; James Polli; William R Proctor; Alexandre Ribeiro; Jian-Ying Wang; Ronald L Wange; Shiew-Mei Huang
Journal:  Clin Transl Sci       Date:  2021-06-16       Impact factor: 4.438

7.  Drug Disposition Protein Quantification in Matched Human Jejunum and Liver From Donors With Obesity.

Authors:  Christine Wegler; Jacek R Wiśniewski; Ida Robertsen; Hege Christensen; Jens Kristoffer Hertel; Jøran Hjelmesaeth; Rasmus Jansson-Löfmark; Anders Åsberg; Tommy B Andersson; Per Artursson
Journal:  Clin Pharmacol Ther       Date:  2022-03-06       Impact factor: 6.903

Review 8.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

9.  Inter-individual and inter-regional variations in enteric drug metabolizing enzyme activities: Results with cryopreserved human intestinal mucosal epithelia (CHIM) from the small intestines of 14 donors.

Authors:  Albert P Li; Ming-Chih D Ho; Novera Alam; Walter Mitchell; Susan Wong; Zhengyin Yan; Jane R Kenny; Cornelis E C A Hop
Journal:  Pharmacol Res Perspect       Date:  2020-10

10.  Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics.

Authors:  Zubida M Al-Majdoub; Narciso Couto; Brahim Achour; Matthew D Harwood; Gordon Carlson; Geoffrey Warhurst; Jill Barber; Amin Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2020-12-05       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.